MTL Cannabis (CSE:MTLC) Third Quarter 2023 Results
Key Financial Results
- Revenue: CA$6.72m (up 30% from 3Q 2022).
- Net loss: CA$1.74m (loss narrowed by 48% from 3Q 2022).
- CA$0.038 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
MTL Cannabis shares are down 22% from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for MTL Cannabis (1 doesn't sit too well with us!) that we have uncovered.
Valuation is complex, but we're helping make it simple.
Find out whether MTL Cannabis is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CNSX:MTLC
MTL Cannabis
MTL Cannabis Corp., through its subsidiaries, engages in cultivation and production of cannabis products for medical purposes in Canada.
Overvalued with worrying balance sheet.
